Gilead Sciences, Inc. (GILD) KPIs and segments
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Gilead Sciences · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Gilead Sciences: 40 chỉ số vận hành, trong đó có Total revenues, Consolidated revenues — United States và Total HIV Franchise Product Sales, lấy từ 188 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product sales($M)3 | 8,289 | 7,627 | 6,946 | 7,902 | 7,345 | 7,054 | 6,613 | 7,536 | 7,515 | 6,912 | 6,647 | 7,070 | |
United States($M) | 6,361 | 5,601 | 4,926 | 5,873 | 5,274 | 5,038 | 4,631 | 5,550 | 5,433 | 4,916 | 4,609 | 5,181 | |
Europe($M) | 1,058 | 1,155 | 1,137 | 1,222 | 1,144 | 1,178 | 1,073 | 1,160 | 1,154 | 1,118 | 1,144 | 1,128 | |
Rest of World($M) | 869 | 872 | 883 | 809 | 928 | 838 | 909 | 826 | 928 | 878 | 894 | 762 | |
Biktarvy($M)3 | 4,059 | 3,772 | 3,361 | 3,968 | 3,686 | 3,530 | 3,150 | 3,774 | 3,472 | 3,232 | 2,946 | 3,109 | |
United States($M) | 3,284 | 2,981 | 2,573 | 3,255 | 2,940 | 2,799 | 2,474 | 3,129 | 2,826 | 2,585 | 2,315 | 2,588 | |
Europe($M) | 442 | 468 | 437 | 445 | 427 | 429 | 375 | 399 | 375 | 370 | 365 | 333 | |
Rest of World($M) | 333 | 323 | 352 | 268 | 320 | 302 | 301 | 246 | 272 | 277 | 265 | 188 | |
Descovy($M)3 | 1,046 | 967 | 807 | 819 | 701 | 653 | 586 | 617 | 586 | 485 | 426 | 510 | |
United States($M) | 998 | 921 | 761 | 768 | 652 | 601 | 538 | 563 | 534 | 434 | 371 | 457 | |
Rest of World($M) | 26 | 23 | 23 | 24 | 25 | 28 | 27 | 28 | 28 | 26 | 29 | 28 | |
Europe($M) | 22 | 23 | 23 | 26 | 23 | 24 | 21 | 25 | 24 | 25 | 26 | 25 | |
Intangible asset Trodelvy($M)3 | 506 | 457 | 402 | 384 | 357 | 364 | 293 | 355 | 332 | 320 | 309 | 299 | |
United States($M) | 336 | 307 | 253 | 251 | 221 | 224 | 181 | 247 | 226 | 224 | 206 | 226 | |
Europe($M) | 98 | 92 | 95 | 88 | 89 | 96 | 75 | 77 | 80 | 69 | 68 | 48 | |
Rest of World($M) | 71 | 57 | 54 | 45 | 47 | 44 | 37 | 31 | 26 | 26 | 36 | 24 | |
Genvoya($M)3 | 339 | 289 | 264 | 380 | 377 | 377 | 364 | 470 | 449 | 440 | 403 | 516 | |
United States($M) | 301 | 236 | 215 | 331 | 323 | 322 | 305 | 410 | 384 | 372 | 332 | 447 | |
Europe($M) | 27 | 37 | 33 | 34 | 34 | 40 | 40 | 42 | 44 | 45 | 49 | 48 | |
Rest of World($M) | 12 | 16 | 16 | 15 | 19 | 16 | 19 | 18 | 21 | 23 | 21 | 22 | |
Vemlidy($M)3 | 333 | 289 | 237 | 287 | 280 | 252 | 252 | 260 | 232 | 243 | 225 | 217 | |
United States($M) | 170 | 124 | 91 | 149 | 136 | 122 | 100 | 148 | 126 | 117 | 95 | 115 | |
Rest of World($M) | 151 | 152 | 132 | 125 | 132 | 117 | 140 | 100 | 95 | 115 | 119 | 92 | |
Europe($M) | 13 | 13 | 13 | 13 | 12 | 13 | 12 | 11 | 11 | 11 | 11 | 10 | |
Yeztugo($M)3 | 305 | 232 | 166 | 39 | 15 | 0 | |||||||
United States($M) | 294 | 223 | 158 | 39 | 15 | 0 | |||||||
Rest of World($M) | 10 | 9 | 7 | 0 | 0 | 0 | |||||||
Europe($M) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
Yescarta($M)3 | 294 | 346 | 332 | 368 | 349 | 393 | 386 | 389 | 387 | 414 | 380 | ||
United States($M) | 114 | 132 | 120 | 151 | 123 | 162 | 160 | 160 | 145 | 186 | 170 | ||
Europe($M) | 107 | 139 | 146 | 143 | 151 | 154 | 149 | 157 | 182 | 169 | 158 | ||
Rest of World($M) | 73 | 75 | 67 | 75 | 75 | 77 | 77 | 72 | 60 | 58 | 52 | ||
Odefsey($M)3 | 286 | 239 | 221 | 310 | 277 | 298 | 281 | 336 | 326 | 315 | 310 | 339 | |
United States($M) | 226 | 171 | 153 | 239 | 206 | 221 | 215 | 252 | 248 | 233 | 223 | 258 | |
Europe($M) | 52 | 58 | 59 | 62 | 61 | 66 | 57 | 73 | 69 | 72 | 76 | 71 | |
Rest of World($M) | 8 | 10 | 9 | 10 | 10 | 11 | 10 | 11 | 9 | 10 | 11 | 11 | |
Sofosbuvir/Velpatasvir($M)3 | 274 | 303 | 283 | 276 | 309 | 342 | 346 | 330 | 385 | 476 | 405 | 378 | |
United States($M) | 139 | 142 | 141 | 139 | 146 | 184 | 166 | 185 | 222 | 267 | 248 | 216 | |
Rest of World($M) | 76 | 80 | 82 | 71 | 97 | 76 | 99 | 75 | 96 | 126 | 78 | 89 | |
Europe($M) | 59 | 81 | 60 | 65 | 65 | 81 | 80 | 69 | 67 | 84 | 79 | 73 | |
Livdelzi($M)3 | 203 | 167 | 133 | 105 | 78 | 40 | |||||||
United States($M) | 176 | 147 | 115 | 93 | 74 | 40 | |||||||
Europe($M) | 26 | 20 | 18 | 11 | 4 | 0 | |||||||
Rest of World($M) | 1 | 0 | 0 | 0 | 0 | 0 | |||||||
Symtuza - Revenue share($M)3 | 132 | 138 | 138 | 133 | 124 | 124 | 114 | 144 | 139 | 168 | 141 | ||
United States($M) | 103 | 105 | 107 | 98 | 95 | 88 | 82 | 112 | 103 | 131 | 104 | ||
Europe($M) | 26 | 30 | 28 | 32 | 26 | 33 | 29 | 29 | 33 | 34 | 33 | ||
Rest of World($M) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||
Other Liver Disease($M)3 | 117 | 118 | 114 | 504 | 126 | 123 | 121 | 130 | 116 | 113 | 107 | 96 | |
Europe($M) | 62 | 79 | 78 | 112 | 70 | 72 | 76 | 54 | 54 | 47 | 47 | 38 | |
United States($M) | 39 | 20 | 15 | 376 | 39 | 33 | 28 | 58 | 45 | 47 | 42 | 39 | |
Rest of World($M) | 16 | 19 | 21 | 17 | 17 | 19 | 17 | 18 | 17 | 19 | 19 | 19 | |
AmBisome($M)3 | 99 | 110 | 138 | 118 | 123 | 129 | 139 | 109 | 130 | 151 | 144 | 111 | |
Europe($M) | 52 | 47 | 59 | 66 | 69 | 65 | 67 | 66 | 71 | 69 | 70 | 68 | |
Rest of World($M) | 44 | 59 | 72 | 46 | 52 | 56 | 66 | 36 | 52 | 65 | 60 | 39 | |
United States($M) | 3 | 4 | 7 | 5 | 2 | 7 | 5 | 7 | 6 | 17 | 14 | 4 | |
Veklury($M)3 | 86 | 23 | 144 | 211 | 277 | 121 | 302 | 338 | 692 | 214 | 555 | 719 | |
United States($M) | 63 | 14 | 112 | 80 | 140 | 51 | 199 | 108 | 393 | 76 | 315 | 365 | |
Europe($M) | 12 | 2 | 14 | 67 | 43 | 19 | 22 | 80 | 81 | 53 | 70 | 181 | |
Rest of World($M) | 11 | 7 | 18 | 65 | 93 | 50 | 82 | 150 | 219 | 85 | 169 | 175 | |
Other HIV($M)3 | 82 | 56 | 73 | 244 | 73 | 92 | 91 | 112 | 100 | 105 | 117 | 80 | |
United States($M) | 55 | 23 | 36 | 208 | 43 | 50 | 50 | 67 | 65 | 65 | 60 | 46 | |
Europe($M) | 22 | 24 | 27 | 24 | 22 | 33 | 31 | 33 | 26 | 25 | 45 | 25 | |
Rest of World($M) | 5 | 10 | 9 | 12 | 8 | 9 | 10 | 12 | 9 | 15 | 12 | 9 | |
Other($M)3 | 68 | 51 | 58 | 86 | 61 | 73 | 70 | 75 | 71 | 130 | 80 | 90 | |
United States($M) | 36 | 22 | 39 | 52 | 34 | 44 | 47 | 52 | 47 | 98 | 59 | 64 | |
Rest of World($M) | 25 | 21 | 11 | 26 | 20 | 21 | 14 | 16 | 16 | 24 | 12 | 17 | |
Europe($M) | 8 | 8 | 8 | 9 | 7 | 8 | 9 | 8 | 8 | 8 | 9 | 9 | |
Tecartus($M)3 | 60 | 70 | 75 | 90 | 83 | 92 | 78 | 98 | 98 | 107 | 100 | 98 | |
Europe($M) | 31 | 34 | 37 | 51 | 35 | 41 | 31 | 36 | 29 | 37 | 36 | 27 | |
United States($M) | 24 | 29 | 30 | 31 | 40 | 41 | 40 | 53 | 63 | 63 | 55 | 66 | |
Rest of World($M) | 5 | 8 | 8 | 7 | 8 | 9 | 8 | 9 | 6 | 7 | 8 | 4 | |
Royalty, contract and other revenues($M)3 | 11 | 176 | 14 | 22 | 424 | 27 | 54 | 33 | 30 | 41 | 39 | 44 | |
Europe($M) | 6 | 169 | 8 | 14 | 411 | 10 | 11 | 15 | 13 | 15 | 15 | 37 | |
Rest of World($M) | 3 | 4 | 6 | 4 | 5 | 4 | 6 | 2 | 1 | 1 | 1 | 3 | |
United States($M) | 2 | 2 | 0 | 3 | 7 | 13 | 37 | 16 | 17 | 25 | 23 | 5 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)8 | |||||||||||||
United States($M) | 6,363 | 5,603 | 4,926 | 5,876 | 5,281 | 5,051 | 4,668 | 5,567 | 5,450 | 4,941 | 4,633 | 5,185 | |
Europe($M) | 1,065 | 1,324 | 1,144 | 1,236 | 1,555 | 1,189 | 1,084 | 1,175 | 1,167 | 1,133 | 1,159 | 1,164 | |
Rest of World($M) | 872 | 876 | 889 | 813 | 933 | 842 | 915 | 826 | 929 | 879 | 894 | 765 | |
Total revenues ($M)($M)3 | 7,803 | 6,960 | 7,925 | 7,769 | 7,082 | 6,667 | 7,569 | 7,545 | 6,954 | 6,686 | 7,114 | ||
Total revenues YoY growth (%)(%) | 10.0% | 4.0% | 5.0% | 3.0% | 2.0% | 6.0% | 7.0% | 5.0% | 5.0% | -4.0% | |||
Total product sales ($M)($M)5 | 7,627 | 6,946 | 7,902 | 7,345 | 7,054 | 6,613 | 7,536 | 7,515 | 6,912 | 6,647 | 7,070 | ||
Total product sales excluding Veklury (Base business, $M)($M)1 | 7,604 | 6,802 | 7,691 | 7,068 | 6,934 | 6,311 | 7,198 | 6,823 | 6,698 | 6,092 | 6,350 | ||
Product sales ex-Veklury YoY growth (%)(%) | 10.0% | 8.0% | 7.0% | 4.0% | 4.0% | 4.0% | 13.0% | 7.0% | 6.0% | 6.0% | -24.0% | ||
Total product sales — U.S. ($M)($M) | 5,601 | 4,926 | 5,873 | 5,274 | 5,038 | 4,631 | 5,550 | 5,433 | 4,916 | 4,609 | 5,181 | ||
Total product sales — Europe ($M)($M) | 1,155 | 1,137 | 1,222 | 1,144 | 1,178 | 1,073 | 1,160 | 1,154 | 1,118 | 1,144 | 1,128 | ||
Total product sales — Rest of World ($M)($M) | 872 | 883 | 809 | 928 | 838 | 909 | 826 | 928 | 878 | 894 | 762 | ||
Total product sales YoY growth (%)(%) | 8.0% | 5.0% | 5.0% | -2.0% | 2.0% | -1.0% | 7.0% | 7.0% | 5.0% | 5.0% | -4.0% | ||
Royalty, contract and other revenues ($M)($M)4 | 176 | 14 | 22 | 424 | 27 | 54 | 33 | 30 | 41 | 39 | 44 | ||
Royalty, contract and other revenues — U.S. ($M)($M) | 2 | 0 | 3 | 7 | 13 | 37 | 16 | 17 | 25 | 23 | 5 | ||
Royalty, contract and other revenues — Europe ($M)($M) | 169 | 8 | 14 | 411 | 10 | 11 | 15 | 13 | 15 | 15 | 37 | ||
Royalty, contract and other revenues — Rest of World ($M)($M) | 4 | 6 | 4 | 5 | 4 | 6 | 2 | 1 | 1 | 1 | 3 | ||
Royalty, contract and other revenues YoY growth (%)(%) | -75.0% | -35.0% | -34.0% | 37.0% | -26.0% | -46.0% | 18.0% | -15.0% | -21.0% | ||||
Total HIV Franchise Product Sales ($M)($M)4 | 5,693 | 5,030 | 5,800 | 5,277 | 5,088 | 4,587 | 5,452 | 5,073 | 4,745 | 4,342 | 4,693 | ||
Total HIV Franchise Product Sales — U.S. sales ($M)($M) | 4,659 | 4,004 | 4,845 | 4,299 | 4,096 | 3,664 | 4,532 | 4,161 | 3,821 | 3,405 | 3,899 | ||
Total HIV Franchise Product Sales — Europe sales ($M)($M) | 640 | 607 | 623 | 592 | 624 | 553 | 602 | 570 | 571 | 596 | 534 | ||
Total HIV Franchise Product Sales — Rest of World sales ($M)($M) | 393 | 419 | 332 | 386 | 368 | 370 | 317 | 342 | 353 | 342 | 261 | ||
Total HIV Franchise Product Sales — Worldwide YoY growth (%)(%) | 12.0% | 10.0% | 6.0% | 4.0% | 7.0% | 6.0% | 16.0% | 9.0% | 3.0% | 4.0% | -2.0% | ||
Total Liver Disease Franchise Product Sales ($M)($M)6 | 877 | 767 | 845 | 819 | 795 | 758 | 719 | 733 | 832 | 737 | 691 | ||
Total Liver Disease Franchise Product Sales — U.S. sales ($M)($M) | 433 | 362 | 457 | 414 | 413 | 335 | 391 | 393 | 431 | 385 | 370 | ||
Total Liver Disease Franchise Product Sales — Europe sales ($M)($M) | 193 | 170 | 175 | 158 | 170 | 168 | 134 | 132 | 142 | 137 | 121 | ||
Total Liver Disease Franchise Product Sales — Rest of World sales ($M)($M) | 251 | 235 | 213 | 247 | 211 | 256 | 194 | 207 | 259 | 215 | 200 | ||
Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%)(%) | 10.0% | 1.0% | 17.0% | 12.0% | -4.0% | 3.0% | 4.0% | 4.0% | 17.0% | 9.0% | -1.0% | ||
Total HCV Franchise (legacy sub-franchise breakout) ($M)($M)3 | 432 | ||||||||||||
Total HCV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)($M) | 251 | ||||||||||||
Total HCV Franchise (legacy sub-franchise breakout) — Europe sales ($M)($M) | 84 | ||||||||||||
Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)($M) | 97 | ||||||||||||
Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M)($M)3 | 259 | ||||||||||||
Total HBV / HDV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)($M) | 119 | ||||||||||||
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Europe sales ($M)($M) | 37 | ||||||||||||
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)($M) | 103 | ||||||||||||
Veklury (remdesivir — COVID-19 antiviral) ($M)($M)1 | 23 | 144 | 211 | 277 | 121 | 302 | 338 | 692 | 214 | 555 | 719 | ||
Veklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%)(%) | -81.0% | -52.0% | -37.0% | -60.0% | -44.0% | -45.0% | -53.0% | 9.0% | -16.0% | -3.0% | -28.0% | ||
Total Oncology Franchise Product Sales ($M)($M)5 | 873 | 810 | 841 | 788 | 849 | 757 | 843 | 816 | 841 | 789 | 765 | ||
Total Oncology Franchise Product Sales — U.S. sales ($M)($M) | 468 | 403 | 434 | 384 | 427 | 381 | 460 | 433 | 474 | 431 | 479 | ||
Total Oncology Franchise Product Sales — Europe sales ($M)($M) | 265 | 278 | 281 | 275 | 291 | 255 | 270 | 291 | 275 | 262 | 215 | ||
Total Oncology Franchise Product Sales — Rest of World sales ($M)($M) | 140 | 129 | 127 | 129 | 131 | 121 | 113 | 92 | 92 | 96 | 71 | ||
Total Oncology Franchise Product Sales — Worldwide YoY growth (%)(%) | 3.0% | 7.0% | 4.0% | -3.0% | 1.0% | -4.0% | 10.0% | 6.0% | 15.0% | 18.0% | 24.0% | ||
Total Kite Cell Therapy Product Sales ($M)($M)3 | 417 | 407 | 458 | 432 | 485 | 464 | 488 | 485 | 521 | 480 | 467 | ||
Total Kite Cell Therapy Product Sales — U.S. sales ($M)($M) | 161 | 150 | 182 | 163 | 203 | 200 | 213 | 208 | 250 | 225 | 253 | ||
Total Kite Cell Therapy Product Sales — Europe sales ($M)($M) | 173 | 183 | 193 | 186 | 196 | 180 | 193 | 211 | 206 | 195 | 167 | ||
Total Kite Cell Therapy Product Sales — Rest of World sales ($M)($M) | 83 | 74 | 82 | 83 | 86 | 84 | 82 | 66 | 66 | 60 | 47 | ||
Total Other Products Sales ($M)($M)4 | 161 | 196 | 205 | 184 | 202 | 209 | 184 | 201 | 280 | 224 | 201 | ||
Total Other Products Sales — U.S. sales ($M)($M) | 26 | 46 | 57 | 36 | 52 | 52 | 58 | 53 | 115 | 73 | 68 | ||
Total Other Products Sales — Europe sales ($M)($M) | 55 | 67 | 75 | 76 | 73 | 76 | 74 | 80 | 77 | 79 | 77 | ||
Total Other Products Sales — Rest of World sales ($M)($M) | 80 | 83 | 72 | 72 | 77 | 81 | 52 | 68 | 88 | 71 | 56 | ||
Other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M)($M)1 | 51 | 58 | 86 | 61 | 73 | 70 | 75 | 71 | 130 | 80 | 90 | ||
Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Worldwide YoY growth (%)(%) | -20.0% | -6.0% | 11.0% | -8.0% | -28.0% | -7.0% | -8.0% | -7.0% | 15.0% | 13.0% | -20.0% | ||
Accrued rebates and chargebacks liability (Balance Sheet, $M)($M) | 4,233 | 4,118 | 4,337 | 4,931 | 4,215 | 4,185 | 3,892 | 4,113 | 3,923 | 4,263 | 3,802 | ||
GAAP Research and development (R&D) expenses ($M)($M)3 | 1,764 | 1,372 | 1,584 | 1,346 | 1,491 | 1,379 | 1,641 | 1,395 | 1,351 | 1,520 | 1,408 | ||
R&D by cost type — Personnel, infrastructure and other support costs ($M)($M) | 1,146 | 861 | 911 | 807 | 855 | 854 | 954 | 808 | 830 | 963 | 823 | ||
R&D by cost type — Clinical studies and outside services / other costs ($M)($M) | 618 | 510 | 673 | 539 | 636 | 524 | 687 | 587 | 520 | 557 | 585 | ||
Non-GAAP Research and development expenses ($M)($M)1 | 1,764 | 1,372 | 1,584 | 1,346 | 1,491 | 1,379 | 1,641 | 1,395 | 1,351 | 1,520 | 1,408 | ||
Non-GAAP R&D expenses as % of total revenues (%)(%) | 22.6% | 19.7% | 20.0% | 17.3% | 21.1% | 20.7% | 21.7% | 18.5% | 19.4% | 22.7% | 19.8% | ||
Acquired in-process research and development (IPR&D) expenses ($M)($M)1 | 11,183 | 107 | 539 | 170 | 61 | 253 | -11 | 505 | 38 | 4,131 | 347 | ||
In-process research and development (IPR&D) impairment charges ($M)($M) | 12,043 | 107 | 539 | 170 | 61 | 253 | -11 | 505 | 38 | 4,131 | 347 | ||
Equity method & fair value option biotech investments carrying value ($M)($M)3 | 295 | 308 | 393 | 393 | 369 | 359 | 386 | 382 | 376 | 359 | 340 | ||
Equity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M)($M) | 969 | 679 | 749 | 427 | 448 | ||||||||
Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M)($M) | 500 | 504 | 551 | 570 | 462 | ||||||||
Other equity method investments (incl. Assembly Biosciences) — Fair value carrying amount ($M)($M) | 171 | 155 | 183 | 143 | 53 | ||||||||
Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M)($M)7 | 33 | 7 | 11 | 6 | 8 | 8 | 23 | 7 | 11 | 10 | -49 | ||
Arcus revenue from Gilead — Other collaboration revenue ($M)($M) | 25 | 5 | 4 | 6 | 8 | 8 | 8 | 7 | 11 | 10 | 9 | ||
Arcus total other collaboration revenue ($M)($M) | 25 | 5 | 4 | 6 | 8 | 8 | 8 | 7 | 11 | 10 | 9 | ||
Arcus revenue from Gilead — License & development services (legacy axis, $M)($M) | 8 | 10 | 152 | 20 | |||||||||
Arcus Biosciences — Total operating expenses ($M)($M)2 | 137 | 151 | 147 | 168 | 168 | 150 | 129 | 153 | 145 | 161 | 122 | ||
Arcus Biosciences — Research and development (R&D) expense ($M)($M) | 113 | 122 | 121 | 141 | 139 | 122 | 101 | 123 | 115 | 109 | 93 | ||
Arcus Biosciences — General and administrative (G&A) expense ($M)($M) | 24 | 29 | 26 | 27 | 29 | 28 | 28 | 30 | 30 | 32 | 29 | ||
Arcus Biosciences — Operating income (loss) ($M)($M) | -96 | -134 | -114 | -142 | -8 | -122 | -103 | -105 | -106 | -16 | -91 | ||
Arcus Biosciences — Net income (loss) ($M)($M)2 | -91 | -128 | -106 | -135 | 0 | -112 | -94 | -92 | -93 | -4 | -81 | ||
Arcus Biosciences — Diluted EPS ($/sh)($) | -0.72 | -1.02 | -1.27 | 0 | -1.14 | -1 | -1.02 | -0.05 | |||||
Arcus Biosciences — Diluted weighted-average shares (M shares) | 126 | 125 | 4 | 107 | 107 | 98 | 1 | 91 | 91 | 86 | 0 | ||
Arcus Biosciences — Total assets ($M)($M)6 | 924 | 997 | 1,139 | 974 | 1,075 | 1,156 | 1,150 | 1,252 | 1,186 | 1,293 | 1,095 | ||
Arcus Biosciences — Cash and cash equivalents ($M)($M) | 150 | 201 | 222 | 238 | 248 | 192 | 150 | 201 | 156 | 185 | 127 | ||
Arcus Biosciences — Marketable securities, current ($M)($M) | 552 | 621 | 759 | 593 | 663 | 805 | 828 | 888 | 813 | 810 | 632 | ||
Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M)($M) | 36 | 3 | 11 | 11 | 15 | 15 | 20 | 16 | 28 | 35 | 38 | ||
Arcus Biosciences — Deferred collaboration revenue, current ($M)($M) | 19 | 34 | 35 | 52 | 71 | 72 | 85 | 105 | 113 | 124 | 91 | ||
Arcus Biosciences — Deferred collaboration revenue, noncurrent ($M)($M) | 37 | 45 | 43 | 53 | 60 | 219 | 234 | 289 | 214 | 242 | 307 | ||
Arcus Biosciences — Total current liabilities ($M)($M) | 198 | 209 | 231 | 235 | 210 | 192 | 226 | 215 | 199 | 204 | 184 | ||
Non-GAAP product gross margin (%)(%)4 | 79.3% | 79.2% | 79.5% | 78.6% | 78.7% | 76.7% | 79.0% | 79.1% | 77.7% | 76.6% | 70.4% | ||
GAAP product gross margin (%)(%) | 79.3% | 79.2% | 79.5% | 78.6% | 78.7% | 76.7% | 79.0% | 79.1% | 77.7% | 76.6% | 70.4% | ||
Non-GAAP cost of goods sold ($M)($M) | 1,579 | 1,445 | 1,623 | 1,569 | 1,501 | 1,540 | 1,581 | 1,574 | 1,544 | 1,552 | 2,090 | ||
GAAP cost of goods sold ($M)($M) | 1,579 | 1,445 | 1,623 | 1,569 | 1,501 | 1,540 | 1,581 | 1,574 | 1,544 | 1,552 | 2,090 | ||
Non-GAAP COGS adjustments (Acquired intangible amortization & step-up, $M)($M) | 579 | 576 | 579 | 577 | 579 | 579 | 579 | 579 | 579 | 579 | 1,110 | ||
Non-GAAP operating margin (%)(%)3 | -133.2% | 37.2% | 25.0% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% | 38.0% | -64.6% | 22.7% | ||
GAAP operating margin (%)(%) | -133.2% | 37.2% | 25.0% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% | 38.0% | -64.6% | 22.7% | ||
Non-GAAP operating income (loss) ($M)($M) | -10,394 | 2,586 | 1,984 | 3,921 | 2,474 | 2,237 | 2,451 | 3,258 | 3,265 | -4,322 | 1,612 | ||
Non-GAAP selling, general and administrative (SG&A) expenses ($M)($M)2 | 1,921 | 1,451 | 1,794 | 1,357 | 1,365 | 1,258 | 1,906 | 1,433 | 1,377 | 1,375 | 1,608 | ||
Non-GAAP SG&A expenses as % of total revenues (%)(%) | 24.6% | 20.9% | 22.6% | 17.5% | 19.3% | 18.9% | 25.2% | 19.0% | 19.8% | 20.6% | 22.6% | ||
Non-GAAP SG&A adjustments ($M)($M) | 400 | 88 | 106 | 5 | 7 | 36 | 54 | 28 | 26 | 80 | 11 | ||
Non-GAAP net income (loss) attributable to Gilead ($M)($M)4 | -10,496 | 2,021 | 2,183 | 3,095 | 1,960 | 1,315 | 1,783 | 2,531 | 2,519 | -4,170 | 1,417 | ||
Non-GAAP diluted earnings (loss) per share ($/sh)($) | -8.45 | 1.61 | 1.86 | 2.47 | 1.56 | 1.04 | 1.90 | 2.02 | 2.01 | -1.32 | 1.72 | ||
Non-GAAP effective tax rate (%)(%) | -2.4% | 21.7% | -5.0% | 16.2% | 19.3% | 20.2% | 17.8% | -31.1% | 21.4% | 7.0% | 14.3% | ||
GAAP effective tax rate (%)(%) | -2.4% | 21.7% | -5.0% | 16.2% | 19.3% | 20.2% | 17.8% | -31.1% | 21.4% | 7.0% | 14.3% | ||
Total non-GAAP adjustments before income taxes ($M)($M)6 | 2,722 | 539 | 852 | 112 | 675 | 1,082 | 789 | 2,113 | 1,012 | 3,219 | 938 | ||
Total non-GAAP adjustments to costs and expenses ($M)($M) | 3,065 | 681 | 1,104 | 594 | 817 | 656 | 663 | 2,370 | 620 | 3,205 | 1,127 | ||
Non-GAAP R&D adjustments ($M)($M) | 335 | 17 | 19 | 12 | 41 | 40 | 29 | 13 | 16 | 117 | -44 | ||
Non-GAAP other income (expense) adjustments (equity securities fair value, $M)($M) | -343 | -142 | -252 | -483 | -142 | 426 | 126 | -258 | 392 | 14 | -189 | ||
Income tax effect of non-GAAP adjustments ($M)($M) | -574 | -58 | -252 | -79 | -162 | -154 | -152 | -521 | -168 | -732 | -218 | ||
Discrete and related tax charges (benefits) ($M)($M) | 44 | -46 | 454 | -11 | -48 | -42 | 29 | 314 | -60 | -39 | -12 | ||
Total non-GAAP adjustments after tax ($M)($M) | 2,105 | 528 | 146 | 43 | 560 | 970 | 607 | 1,278 | 905 | 2,526 | 732 | ||
Non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M)($M)2 | 3,432 | 2,427 | 3,121 | 3,962 | 720 | 1,653 | 2,828 | 4,169 | 1,195 | 2,114 | 1,954 | ||
Operating cash flow (Form 8-K Selected Cash Flow Information, $M)($M) | 3,573 | 2,544 | 3,326 | 4,109 | 827 | 1,757 | 2,975 | 4,309 | 1,325 | 2,219 | 2,168 | ||
Capital expenditures (Form 8-K Selected Cash Flow Information, $M)($M) | 140 | 117 | 205 | 147 | 107 | 104 | 147 | 140 | 130 | 105 | 214 | ||
Total inventories (Current + Noncurrent, $M)($M)5 | 4,298 | 4,339 | 4,368 | 4,387 | 3,913 | 3,778 | 3,589 | 3,435 | 3,388 | 3,363 | 3,366 | ||
Inventories — Raw materials ($M)($M) | 1,415 | 1,357 | 1,414 | 1,396 | 1,271 | 1,196 | 1,295 | 1,332 | 1,259 | 1,237 | 1,246 | ||
Inventories — Work in process ($M)($M) | 1,163 | 1,276 | 1,306 | 1,341 | 1,039 | 1,076 | 847 | 684 | 803 | 778 | 847 | ||
Inventories — Finished goods ($M)($M) | 1,719 | 1,706 | 1,647 | 1,650 | 1,603 | 1,506 | 1,447 | 1,419 | 1,326 | 1,348 | 1,272 | ||
Inventories — Current portion (Balance Sheet, $M)($M) | 1,953 | 1,914 | 1,774 | 1,785 | 1,825 | 1,759 | 1,710 | 1,869 | 2,026 | 1,853 | 1,787 | ||
Inventories — Noncurrent portion (included in Other long-term assets, $M)($M) | 2,345 | 2,424 | 2,594 | 2,602 | 2,087 | 2,018 | 1,879 | 1,566 | 1,362 | 1,510 | 1,578 | ||
Property, plant and equipment, net ($M)($M)2 | 5,833 | 5,638 | 5,606 | 5,500 | 5,459 | 5,421 | 5,414 | 5,391 | 5,346 | 5,321 | 5,317 | ||
Property, plant and equipment, gross ($M)($M) | 8,707 | 8,422 | 8,302 | 8,193 | 8,080 | 7,963 | 7,884 | 7,766 | |||||
Accumulated depreciation ($M)($M) | 2,874 | 2,784 | 2,696 | 2,693 | 2,621 | 2,542 | 2,470 | 2,449 | |||||
Intangible assets, net ($M)($M)3 | 14,032 | 16,382 | 16,978 | 17,970 | 18,566 | 19,355 | 19,948 | 20,546 | 22,832 | 23,428 | 26,454 | ||
Goodwill ($M)($M) | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | ||
Finite-lived intangible assets, net ($M)($M)7 | 14,032 | 14,082 | 14,678 | 15,270 | 15,866 | 16,465 | 17,058 | 17,656 | 18,192 | 18,788 | 19,384 | ||
Finite-lived intangible assets, gross ($M)($M) | 32,413 | 31,863 | 31,888 | 31,884 | 31,884 | 31,884 | 31,879 | 31,879 | 31,819 | 31,819 | 31,819 | ||
Finite-lived intangible assets — Accumulated amortization ($M)($M) | 18,382 | 17,782 | 17,211 | 16,614 | 16,019 | 15,421 | 14,822 | 14,224 | 13,628 | 13,032 | 12,436 | ||
Trodelvy (sacituzumab govitecan) intangible asset — Net carrying value ($M)($M)2 | 7,026 | 7,296 | 7,566 | 7,836 | 8,107 | 8,377 | 8,647 | 8,917 | 9,187 | 9,458 | 9,728 | ||
Trodelvy intangible asset — Gross ($M)($M) | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | 11,730 | ||
Trodelvy intangible asset — Accumulated amortization ($M)($M) | 4,704 | 4,434 | 4,164 | 3,894 | 3,623 | 3,353 | 3,083 | 2,813 | 2,543 | 2,272 | 2,002 | ||
Sofosbuvir (Epclusa / Harvoni / Vosevi) intangible asset — Net carrying value ($M)($M)2 | 1,923 | 2,097 | 2,272 | 2,447 | 2,622 | 2,797 | 2,971 | 3,146 | 3,321 | 3,496 | 3,670 | ||
Sofosbuvir intangible asset — Gross ($M)($M) | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | 10,720 | ||
Sofosbuvir intangible asset — Accumulated amortization ($M)($M) | 8,797 | 8,623 | 8,448 | 8,273 | 8,098 | 7,923 | 7,749 | 7,574 | 7,399 | 7,224 | 7,050 | ||
Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M)($M)2 | 3,780 | 3,881 | 3,983 | 4,084 | 4,186 | 4,288 | 4,389 | 4,491 | 4,593 | 4,694 | 4,796 | ||
Yescarta intangible asset — Gross ($M)($M) | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | 7,110 | ||
Yescarta intangible asset — Accumulated amortization ($M)($M) | 3,330 | 3,229 | 3,127 | 3,026 | 2,924 | 2,822 | 2,721 | 2,619 | 2,517 | 2,416 | 2,314 | ||
Hepcludex (bulevirtide) intangible asset — Net carrying value ($M)($M)2 | 933 | 408 | 430 | 451 | 473 | 494 | 516 | 537 | 559 | 580 | 602 | ||
Hepcludex intangible asset — Gross ($M)($M) | 1,395 | 845 | 845 | 845 | 845 | 845 | 845 | 845 | 845 | 845 | 845 | ||
Hepcludex intangible asset — Accumulated amortization ($M)($M) | 462 | 437 | 415 | 394 | 372 | 351 | 329 | 308 | 286 | 265 | 243 | ||
Other finite-lived intangible assets — Net carrying value ($M)($M)2 | 372 | 400 | 428 | 451 | 479 | 510 | 535 | 565 | 533 | 560 | 588 | ||
Other finite-lived intangible assets — Gross ($M)($M) | 1,458 | 1,458 | 1,483 | 1,479 | 1,479 | 1,479 | 1,474 | 1,474 | 1,414 | 1,414 | 1,414 | ||
Other finite-lived intangible assets — Accumulated amortization ($M)($M) | 1,087 | 1,059 | 1,056 | 1,028 | 1,001 | 971 | 940 | 911 | 883 | 855 | 827 | ||
Indefinite-lived IPR&D intangible assets ($M)($M)1 | 0 | 2,300 | 2,300 | 2,700 | 2,700 | 2,890 | 2,890 | 2,890 | 4,640 | 4,640 | 7,070 | ||
Indefinite-lived IPR&D — Trodelvy NSCLC (impaired in FY2024, $M)($M) | 1,750 | 1,750 | 1,750 | 1,750 | 1,800 | 1,750 | 1,800 | 5,900 | |||||
Level 3 contingent consideration liabilities ($M)($M)1 | 60 | 275 | 278 | 274 | 271 | 216 | 206 | 222 | 208 | 222 | 228 | ||
Contingent consideration liability — MYR GmbH / Hepcludex ($M)($M) | 60 | 275 | 278 | 274 | 271 | 216 | 206 | 222 | 208 | 222 | 228 | ||
Litigation accrual reserve (Antitrust, patent & product liability, $M)($M) | 0 | 0 | 0 | 0 | 0 | 220 | 242 | 0 | |||||
Restructuring expenses — Total ($M)($M)3 | 17 | 40 | 37 | 14 | 13 | 74 | 76 | 28 | 21 | 63 | |||
Restructuring expenses — Research and development ($M)($M) | 14 | 16 | 8 | 6 | 38 | 30 | 5 | 13 | 50 | ||||
Restructuring expenses — Selling, general and administrative ($M)($M) | 25 | 17 | 5 | 7 | 36 | 46 | 23 | 8 | 13 | ||||
Accrued restructuring liability ($M)($M) | 60 | 73 | 61 | 52 | 92 | 138 | 93 | ||||||
Long-term debt, noncurrent carrying value ($M)($M)3 | 23,832 | 20,861 | 22,129 | 22,135 | 22,140 | 22,146 | 24,896 | 21,437 | 21,540 | 21,527 | 23,189 | ||
Current portion of long-term debt and senior notes ($M)($M) | 2,414 | 1,313 | 2,807 | 2,806 | 2,806 | 2,806 | 1,815 | 1,812 | 1,809 | 3,667 | 1,798 | ||
Total debt carrying value ($M)($M) | 26,246 | 22,174 | 24,937 | 24,941 | 24,946 | 24,952 | 26,710 | 23,249 | 23,349 | 25,193 | 24,987 | ||
Total long-term debt fair value ($M)($M) | 22,262 | 19,178 | 22,342 | 22,398 | 21,981 | 21,886 | 23,335 | 20,931 | 19,841 | 21,930 | 22,567 | ||
Cash dividends declared per share ($/sh)($)3 | 0.82 | 0.82 | 0.79 | 0.79 | 0.79 | 0.77 | 0.77 | 0.77 | |||||
Common stock repurchases — Cash paid ($M)($M) | 355 | 419 | 230 | 435 | 527 | 730 | 350 | 300 | 100 | 400 | 150 | ||
Common stock repurchases — Value retired ($M)($M) | 355 | 419 | 230 | 435 | 527 | 730 | 350 | 300 | 100 | 400 | 150 | ||
Common stock repurchases — Shares repurchased (M shares) | 3 | 3 | 2 | 4 | 5 | 7 | 3 | 4 | 2 | 5 | 2 | ||
Total stock-based compensation (SBC) expense ($M)($M) | 231 | 218 | 230 | 230 | 225 | 209 | 222 | 216 | 210 | 187 | 201 | ||
Income tax expense (benefit) ($M)($M) | 242 | 559 | -105 | 589 | 468 | 334 | 385 | -297 | 438 | -315 | 237 | ||
Global employees headcount (people)1 | |||||||||||||
Deferred compensation plan rabbi trust assets & liabilities ($M)($M) | 458 | 405 | 406 | 401 | 374 | 340 | 343 | 343 | 327 | 318 | 284 | ||
U.S. PPI: Pharmaceutical Preparation Manufacturing (Index Dec 2009=100)1 | |||||||||||||
U.S. PCE: Pharmaceutical and Other Medical Products ($B SAAR) | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | ||
Income Statement — Total revenues ($M)($M)10 | 7,803 | 6,960 | 7,925 | 7,769 | 7,082 | 6,667 | 7,569 | 7,545 | 6,954 | 6,686 | 7,114 | ||
Cost of goods sold ($M)($M) | 1,579 | 1,445 | 1,624 | 1,569 | 1,501 | 1,540 | 1,581 | 1,574 | 1,544 | 1,552 | 2,090 | ||
Research and development expenses ($M)($M) | 1,764 | 1,372 | 1,584 | 1,346 | 1,491 | 1,379 | 1,641 | 1,395 | 1,351 | 1,520 | 1,408 | ||
Selling, general and administrative expenses ($M)($M) | 1,921 | 1,451 | 1,794 | 1,357 | 1,365 | 1,258 | 1,907 | 1,433 | 1,377 | 1,375 | 1,608 | ||
Operating income (loss) ($M)($M) | -10,394 | 2,586 | 1,984 | 3,327 | 2,474 | 2,237 | 2,452 | 888 | 2,644 | -4,322 | 1,612 | ||
Interest expense ($M)($M) | 247 | 240 | 255 | 256 | 254 | 260 | 249 | 238 | 237 | 254 | 252 | ||
Income (loss) before income taxes ($M)($M) | -10,254 | 2,580 | 2,078 | 3,641 | 2,429 | 1,649 | 2,167 | 956 | 2,053 | -4,486 | 1,653 | ||
Income tax expense (benefit) ($M)($M) | 242 | 559 | -105 | 589 | 468 | 334 | 385 | -297 | 438 | -315 | 237 | ||
Net income (loss) attributable to Gilead ($M)($M) | -10,496 | 2,021 | 2,183 | 3,052 | 1,960 | 1,315 | 1,783 | 1,253 | 1,614 | -4,170 | 1,429 | ||
Diluted earnings (loss) per share ($/sh)($) | -8.45 | 1.61 | 2.43 | 1.56 | 1.04 | 1 | 1.29 | -3.34 | |||||
Diluted weighted-average shares (M shares) | 1,243 | 1,254 | 1,254 | 1,255 | 1,259 | 1,254 | 1,251 | 1,247 | |||||
Balance Sheet — Total assets ($M)($M)10 | 49,362 | 56,278 | 59,023 | 58,533 | 55,721 | 56,434 | 58,995 | 54,525 | 53,579 | 56,292 | 62,125 | ||
Accounts receivable, net ($M)($M) | 5,055 | 4,741 | 4,913 | 5,095 | 4,781 | 4,388 | 4,420 | 4,587 | 4,663 | 4,669 | 4,660 | ||
Inventories ($M)($M) | 1,953 | 1,914 | 1,774 | 1,785 | 1,825 | 1,759 | 1,710 | 1,869 | 2,026 | 1,853 | 1,787 | ||
Total current assets ($M)($M) | 13,945 | 18,641 | 18,342 | 17,874 | 14,718 | 16,901 | 19,173 | 14,779 | 12,317 | 14,041 | 16,085 | ||
Property, plant and equipment, net ($M)($M) | 5,833 | 5,638 | 5,606 | 5,500 | 5,459 | 5,421 | 5,414 | 5,391 | 5,346 | 5,321 | 5,317 | ||
Goodwill ($M)($M) | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | ||
Intangible assets, net ($M)($M) | 14,032 | 16,382 | 16,978 | 17,970 | 18,566 | 19,355 | 19,948 | 20,546 | 22,832 | 23,428 | 26,454 | ||
Total current liabilities ($M)($M) | 11,020 | 9,476 | 11,813 | 12,298 | 11,189 | 12,344 | 12,004 | 11,725 | 10,781 | 13,015 | 11,280 | ||
Long-term debt, noncurrent ($M)($M) | 23,832 | 20,861 | 22,129 | 22,135 | 22,140 | 22,146 | 24,896 | 21,437 | 21,540 | 21,527 | 23,189 | ||
Retained earnings ($M)($M) | 2,200 | 14,131 | 13,730 | 12,825 | 11,325 | 10,931 | 11,497 | 11,073 | 11,165 | 10,656 | 16,304 | ||
Total stockholders' equity ($M)($M) | 11,744 | 23,431 | 22,618 | 21,456 | 19,590 | 19,078 | 19,246 | 18,390 | 18,197 | 17,455 | 22,749 | ||
Cash Flow Statement — Operating cash flow ($M)($M)3 | 3,573 | 2,544 | 3,327 | 4,108 | 827 | 1,757 | 2,975 | 4,309 | 1,325 | 2,219 | 2,169 | ||
Capital expenditures ($M)($M) | 140 | 117 | 205 | 147 | 107 | 104 | 147 | 141 | 130 | 105 | 215 | ||
Cash dividends paid ($M)($M) | 1,029 | 1,040 | 994 | 1,005 | 994 | 1,010 | 973 | 983 | 972 | 990 | 943 | ||
Repurchases of common stock ($M)($M) | 355 | 419 | 230 | 435 | 527 | 730 | 350 | 300 | 100 | 400 | 150 | ||
59 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Gilead Sciences, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Gilead operates as a single global biopharmaceutical operating segment (Note 16), so commercial performance is tracked across Therapeutic Area franchises (HIV, Liver Disease, Veklury, Oncology / Cell Therapy & Trodelvy, Other Products) and 2-dimensional Brand × Geography (Worldwide, U.S., Europe, Rest of World) product sales.
- Core commercial, GTN & R&D KPIs (Groups 1–7) cover: (1) Consolidated Revenues ($7,805M in Q2 2026 / $29,440M in FY25), Total Product Sales ($7,629M in Q2 2026 / $28,913M in FY25 across U.S. $5,574M, Europe $1,226M, Rest of World $829M in Q2 2026), Base Business Product Sales excluding Veklury ($7,606M in Q2 2026, +11% YoY / $28,001M in FY25), Royalty/Contract revenues ($176M in Q2 2026 / $527M in FY25), and foreign currency sales share (25% in Q2 2026 / 26% in FY25); (2) HIV Franchise ($5,747M in Q2 2026, +12% YoY / $20,785M in FY25: Biktarvy $3,772M, Descovy $967M, Genvoya $392M, Odefsey $291M, Symtuza revenue share $145M, Yeztugo twice-yearly PrEP injectable $169M in Q2 2026, plus legacy Truvada/Stribild/Complera/Atripla, Biktarvy U.S. HIV treatment share & U.S. PrEP market volume growth); (3) Liver Disease Franchise ($877M in Q2 2026, +10% YoY / $3,172M in FY25: Sofosbuvir/Velpatasvir Epclusa $351M, Vemlidy $276M, Livdelzi PBC launch $167M, Other Liver $83M, plus historical HCV/HBV/HDV breakouts) and Veklury ($23M in Q2 2026 / $911M in FY25); (4) Oncology Franchise ($874M in Q2 2026, +4% YoY / $3,294M in FY25: Kite Cell Therapy $417M [Yescarta $344M, Tecartus $73M] and Trodelvy ADC $457M) & Other Products ($107M in Q2 2026: AmBisome $66M, Other $41M); (5) Gross-to-Net (GTN) deductions ($19,953M or 41% of gross product sales in FY25), 13-year Rebates & Chargebacks rollforward ($5,181M ending balance in FY25; $6,089M accrued at Q2 2026), and Top 3 U.S. wholesaler concentration (McKesson 37%, Cencora 30%, Cardinal Health 12% of FY25 revenues); (6) R&D Cost Structure ($1,764M GAAP R&D in Q2 2026 split between Personnel/Infrastructure $1,146M and Clinical Studies $618M; $11,183M Acquired IPR&D in Q2 2026 from Arcellx/Tubulis/Ouro acquisitions), biotech ownership stakes (Arcus 32.0%, Galapagos 25.1%, Assembly 29.5%), and standalone financial & Gilead-collaboration KPIs of listed oncology affiliate Arcus Biosciences, Inc. (NYSE: RCUS, CIK 0001724521); and (7) GAAP vs. Non-GAAP Reconciliations (86.9% Non-GAAP gross margin in Q2 2026; $8.15 Non-GAAP diluted EPS in FY25; $3,432M Free Cash Flow in Q2 2026).
- Groups 8–12 cover: (8) Inventories by production stage ($2,521M total at Q2 2026: Raw Materials $1,226M, WIP $656M, Finished Goods $639M), PP&E by geography ($6,073M net at Q2 2026), Goodwill ($8,763M) & Drug Intangible Assets ($16,442M net at Q2 2026: Trodelvy $9,779M, Sofosbuvir $1,512M, Yescarta $2,665M, Hepcludex $753M, Bulevirtide IPR&D $300M, plus 5-year future amortization schedule), and Operating Leases ($1,552M ROU assets at Q2 2026); (9) Level 3 Contingent Consideration ($425M at Q2 2026), Litigation Accrual Reserve ($153M at Q2 2026 & TDF/TAF product liability plaintiff counts), and Restructuring; (10) Debt & 5-Year Maturity Schedule ($22,201M noncurrent long-term debt at Q2 2026), Capital Return ($1,030M dividends / $0.82 per share and $376M buybacks in Q2 2026), Stock-Based Compensation by P&L line & award type ($1,039M in FY25), and Income Taxes (DTA/DTL breakdown & UTB rollforward $1,128M at FY25); (11) Global Workforce (~17,000 employees, $200M 401(k) match, $406M deferred compensation plan in FY25), CEO Pay Ratio (119:1 / $238,979 median employee in FY25), Workplace Safety (62 recordable injuries / 0.36 TRIR per 200K hours in FY25), and 9-year Environmental Sustainability inventory (50,391 mt CO2e Scope 1+2 market-based GHG, 1,355,943 mt CO2e Scope 3 GHG, 424,797 MWh energy with 190,154 MWh renewable, 526 ML water withdrawal, 6,230 mt nonhazardous & 3,742 mt hazardous waste in FY25); and (12) U.S. Pharmaceutical & Healthcare FRED Benchmarks & Core Financial Statements (DB).
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'more than 52%' or 'over 40%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-10-29.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Consolidated Revenue Architecture, Base Business (Ex-Veklury) & Geographic Disaggregation
HIV Franchise — Treatment & Prevention (PrEP) Portfolio by Brand × Geography
Liver Disease Franchise (HCV, HBV/HDV, PBC) & Veklury (Remdesivir) by Brand × Geography
Oncology (Kite Cell Therapy & Trodelvy ADC) & Other Products Portfolio by Brand × Geography
Gross-to-Net (GTN) Deductions, Rebates & Chargebacks Rollforward & U.S. Wholesaler Concentration
R&D Cost Structure, Acquired IPR&D & Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS)
- GAAP Research and development (R&D) expenses ($M) ($M)71 kỳ
- Acquired in-process research and development (IPR&D) expenses ($M) ($M)29 kỳ
- Equity method & fair value option biotech investments carrying value ($M) ($M)12 kỳ
- Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M)30 kỳ
GAAP vs. Non-GAAP Profitability Margins, Adjusted Earnings & Reconciliation Adjustments
Manufacturing Inventories by Stage, PP&E by Geography, Drug Intangible Assets & Leases
Contingent Consideration (Level 3), Litigation Reserves & Restructuring Programs
Debt Maturity Profile, Capital Return, Stock-Based Compensation & Income Taxes (DTA/DTL & UTB)
Human Capital, CEO Pay Ratio (DEF 14A), Workplace Safety & Environmental Sustainability (ESG)
- Global employees headcount (people)10 kỳ
- CEO to median employee pay ratio (:1)7 kỳ
- Workplace safety — Total recordable work-related injuries (count)5 kỳ
- Scope 1 + Scope 2 (market-based) greenhouse gas emissions (mt CO2e)7 kỳ
- Total combined energy consumption (MWh)9 kỳ
- Total water withdrawal / usage (Megaliters, ML)7 kỳ
- Total nonhazardous waste disposal (metric tons)7 kỳ
- Total hazardous waste disposal (metric tons)7 kỳ
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Gilead Sciences
- Form 10-Q (filed 2026-08-06) ↗
- Form 10-K (filed 2026-02-24) ↗
- Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
- Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
- Gilead Sustainability / IR (environmental-sustainability-data-performance-tables.pdf) ↗
- Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
- Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
- Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
- Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
- Proxy Statement (DEF 14A) (gild014721-def14a.htm, filed 2026-03-20) ↗
- Gilead Sustainability / IR (2025-impact-report.pdf) ↗
- FRED (PCU325412325412) ↗
See a number that looks wrong?